This website contains promotional content and is intended for Healthcare Professionals

  1. Article
  2. Source: Campus Sanofi
  3. Jul 9, 2025

Rezurock Efficacy

Author: Sanofi

Editorial Team

  
cGVHD Burden
Unmet Need
Rezurock Dosage
Rezurock Efficacy
Rezurock Safety
Rezurock Economic Value

Rezurock demonstrates strong efficacy with durable ORR across all organs and FFS, along with meaningful improvements in various endpoints and QoL, as supported by clinical trials and RWE across diverse markets.1

Clinical Trial (ROCKstar* 36-month follow-up)1-3

   

  • 74%: overall response rate (ORR) at 36 months
  • Subgroups Best ORR
    • 75%: Severe cGVHD patients
    • 72%: Prior ibrutinib cGVHD patients
    • 69%: Prior ruxolitinib cGVHD patients
  • Organ-specific complete response:

   

  • Failure free survival (FFS) 
  • 86%: Overall survival (OS) at 24months
  • 69.9 weeks/16 months: Median duration of response (DoR)
  • 68% of the responders experienced clinically meaningful improvement in the Lee Symptom Scale (LSS)

*All the results are presented for the 200 mg once daily dosage (N=77)

   

RWE

  • 44.2% improvement in ORR at 6 months (ref 4): (space) 39% of patients receiving Rezurock (LOT- episodes = 113) achieved a response (space) 27% of those receiving BAT (LOT-episodes = 245) achieved a response
  • 28% improvement in FFS at 1 year(ref 4): 61.2% of patients treated with Rezurock (LOT-episodes = 113) remained failure-free 47.8% of those on BAT (LOT-episodes = 245) remained failure-free

Belumosudil showcased promising efficacy and safety results with no new safety signals identified. This was consistently demonstrated across various country cohorts:

France: In patients receiving at least two prior lines of therapy (N=68).

Germany and Switzerland: In heavily pretreated patients (N=33).6

Canada: In patients with a history of extensive treatment (N=35).

Spain: In patients receiving at least two prior lines of therapy (N=63).9

Abbreviations

ORR: Overall response rate; FFS: Failure-free survival; QoL:  Quality of life; RWE: Real-world evidence; GI : Gastrointestinal; n: Sample size; DoR: Duration of response; LOT: Line of therapy; BAT: Best available therapies; cGVHD: Chronic graft-versus-host disease.

MAT-KW-2500349  

Related